BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29888758)

  • 1. Mutation Signatures Including APOBEC in Cancer Cell Lines.
    Jarvis MC; Ebrahimi D; Temiz NA; Harris RS
    JNCI Cancer Spectr; 2018 Jan; 2(1):. PubMed ID: 29888758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
    Farmanbar A; Firouzi S; Kneller R; Khiabanian H
    J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
    Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
    J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
    Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
    Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
    Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
    Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes.
    Jeong HY; Yoo J; Kim H; Kim TM
    Genomics Inform; 2021 Dec; 19(4):e40. PubMed ID: 35172473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.
    Glaser AP; Fantini D; Wang Y; Yu Y; Rimar KJ; Podojil JR; Miller SD; Meeks JJ
    Oncotarget; 2018 Jan; 9(4):4537-4548. PubMed ID: 29435122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature.
    Pettersen HS; Galashevskaya A; Doseth B; Sousa MM; Sarno A; Visnes T; Aas PA; Liabakk NB; Slupphaug G; Sætrom P; Kavli B; Krokan HE
    DNA Repair (Amst); 2015 Jan; 25():60-71. PubMed ID: 25486549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC-Induced Mutagenesis in Cancer.
    Mertz TM; Collins CD; Dennis M; Coxon M; Roberts SA
    Annu Rev Genet; 2022 Nov; 56():229-252. PubMed ID: 36028227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
    Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
    Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AID/APOBEC deaminases and cancer.
    Rebhandl S; Huemer M; Greil R; Geisberger R
    Oncoscience; 2015; 2(4):320-33. PubMed ID: 26097867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
    Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer.
    Trevino V
    Mol Genet Genomic Med; 2019 Aug; 7(8):e810. PubMed ID: 31294536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Koutros S; Rao N; Moore LE; Nickerson ML; Lee D; Zhu B; Pardo LA; Baris D; Schwenn M; Johnson A; Jones K; Garcia-Closas M; Prokunina-Olsson L; Silverman DT; Rothman N; Dean M
    Clin Cancer Res; 2021 Jul; 27(13):3725-3733. PubMed ID: 33849962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational processes molding the genomes of 21 breast cancers.
    Nik-Zainal S; Alexandrov LB; Wedge DC; Van Loo P; Greenman CD; Raine K; Jones D; Hinton J; Marshall J; Stebbings LA; Menzies A; Martin S; Leung K; Chen L; Leroy C; Ramakrishna M; Rance R; Lau KW; Mudie LJ; Varela I; McBride DJ; Bignell GR; Cooke SL; Shlien A; Gamble J; Whitmore I; Maddison M; Tarpey PS; Davies HR; Papaemmanuil E; Stephens PJ; McLaren S; Butler AP; Teague JW; Jönsson G; Garber JE; Silver D; Miron P; Fatima A; Boyault S; Langerød A; Tutt A; Martens JW; Aparicio SA; Borg Å; Salomon AV; Thomas G; Børresen-Dale AL; Richardson AL; Neuberger MS; Futreal PA; Campbell PJ; Stratton MR;
    Cell; 2012 May; 149(5):979-93. PubMed ID: 22608084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
    Baker SC; Mason AS; Southgate J
    Eur Urol; 2020 Aug; 78(2):143-147. PubMed ID: 32349929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
    Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications.
    Harris RS
    Genome Med; 2013; 5(9):87. PubMed ID: 24073723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaining insights into relevance across cancers based on mutation features of TP53 gene.
    Mei Y; Liang D; Wang T; Yu D
    Biochem Biophys Rep; 2021 Dec; 28():101165. PubMed ID: 34786492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
    Zhang L; Zhou Y; Cheng C; Cui H; Cheng L; Kong P; Wang J; Li Y; Chen W; Song B; Wang F; Jia Z; Li L; Li Y; Yang B; Liu J; Shi R; Bi Y; Zhang Y; Wang J; Zhao Z; Hu X; Yang J; Li H; Gao Z; Chen G; Huang X; Yang X; Wan S; Chen C; Li B; Tan Y; Chen L; He M; Xie S; Li X; Zhuang X; Wang M; Xia Z; Luo L; Ma J; Dong B; Zhao J; Song Y; Ou Y; Li E; Xu L; Wang J; Xi Y; Li G; Xu E; Liang J; Yang X; Guo J; Chen X; Zhang Y; Li Q; Liu L; Li Y; Zhang X; Yang H; Lin D; Cheng X; Guo Y; Wang J; Zhan Q; Cui Y
    Am J Hum Genet; 2015 Apr; 96(4):597-611. PubMed ID: 25839328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.